InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2026-02-18 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-08-08 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-07-15 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total revenues | $0 | $0-100.0% | $71.2M-68.0% | $222.7M-13.2% | $256.4M |
| Cost of sales | $109.0M+41.6% | $77.0M+71.1% | $45.0M+58.9% | $28.3M+76.9% | $16.0M |
| Research and development | $750.0M+7.4% | $698.0M+7.7% | $648.0M-8.2% | $705.8M+42.0% | $497.2M |
| Selling, general and administrative | $349.0M+8.7% | $321.0M+3.5% | $310.0M+11.5% | $278.1M+26.4% | $220.0M |
| Total operating expenses | $1.21B+10.2% | $1.10B+9.3% | $1.00B-0.9% | $1.01B+38.1% | $733.1M |
| Loss from operations | -$535.0M+0.2% | -$536.0M+5.8% | -$569.0M+12.3% | -$648.9M-70.0% | -$381.7M |
| Interest income | $25.0M-32.4% | $37.0M+37.0% | $27.0M+143.8% | $11.1M+474.4% | $1.9M |
| Non-cash interest expense on liabilities for sales of future royalties | -$62.0M+1.6% | -$63.0M+4.5% | -$66.0M-53.4% | -$43.0M-46.2% | -$29.4M |
| Other income (expense) | $1.0M+120.0% | -$5.0M-400.0% | -$1.0M | — | — |
| Loss before income taxes | -$571.0M-0.7% | -$567.0M+6.9% | -$609.0M+13.2% | -$701.7M-54.9% | -$453.0M |
| (Provision for) benefit from income taxes | -$4.0M-100.0% | -$2.0M-200.0% | $2.0M+135.1% | -$5.7M | — |
| Net loss | -$575.0M-1.1% | -$569.0M+6.3% | -$607.0M+14.2% | -$707.4M-55.8% | -$454.0M |
| Net loss per share, basic | -$5.8M+7.3% | -$6.3M+23.8% | -$8.3M-81421.7% | -$10K-51.0% | -$7K |
| Net loss per share, diluted | -$5.8M+7.3% | -$6.3M+23.8% | -$8.3M-81421.7% | -$10K-51.0% | -$7K |
| Shares used in computing net loss per share, Basic | $98.6M+9.0% | $90.5M+23.1% | $73.5M-99.9% | $69.91B+3.1% | $67.80B |
| Shares used in computing net loss per share, Diluted | $98.6M+9.0% | $90.5M+23.1% | $73.5M-99.9% | $69.91B+3.1% | $67.80B |
| Product sales | |||||
| Total revenues | $0 | $0-100.0% | $71.2M-68.0% | $222.7M-13.2% | $256.4M |
| Royalty revenue | |||||
| Total revenues | $0 | $0-100.0% | $71.2M-68.0% | $222.7M-13.2% | $256.4M |
| Collaboration and license | |||||
| Total revenues | $0 | $0-100.0% | $71.2M-68.0% | $222.7M-13.2% | $256.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Ultragenyx Pharmaceutical (RARE) Garnering Bullish Sentiment With Forthcoming GTX-102 Phase 3 Angelman Trial
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know